Electromed Extends Growth Streak on Record Profits, Operational Strength

NEW PRAGUE, MN – May 12, 2026 – Electromed, Inc. (NYSE American: ELMD) today announced its 14th consecutive quarter of year-over-year growth, reporting record profitability and operating income for its fiscal third quarter ended March 31, 2026. Despite narrowly missing revenue expectations, the company's significant profit surge and operational efficiency gains painted a picture of robust health that resonated positively with analysts.

The medical device maker posted record net income of $3.0 million, or $0.35 per diluted share, a 58.8% jump from the same period last year. This performance comfortably surpassed analyst consensus estimates of $0.30 per share. Net revenues climbed 18.4% to a record $18.6 million, just shy of the projected $19.24 million, yet the firm's ability to convert sales into profit stole the spotlight. Operating income soared an impressive 76.0% to a record $3.8 million, showcasing substantial operating leverage.

A Blueprint for Consistent Performance

The quarter's results extend a remarkable run for the Minnesota-based company, underscoring the success of its focused business model. Electromed operates as a "pure-play" provider of High-Frequency Chest Wall Oscillation (HFCWO) therapy through its flagship SmartVest® Airway Clearance System. This specialized approach appears to be paying dividends in a market with significant unmet needs.

"I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth," said Jim Cunniff, President and Chief Executive Officer, in the company's press release. "Electromed's unique business model created to address the underserved airway clearance market is achieving the desired results we had expected."

The company's financial foundation appears exceptionally strong. As of March 31, Electromed held $17.0 million in cash and had no debt, with a healthy working capital of $40.0 million. This financial stability, combined with a consistent track record, has earned it a "Strong Buy" consensus from market analysts, with some price targets suggesting a potential upside of over 35% from recent levels.

Tapping an Underserved Patient Market

A key driver of Electromed's long-term strategy is the vast, underserved market of patients with bronchiectasis, a chronic lung condition where airways widen, leading to a buildup of excess mucus. The company estimates that of the approximately 824,000 diagnosed patients in the U.S., fewer than 15% currently use HFCWO therapy like the SmartVest.

This presents a significant runway for growth. The global market for bronchiectasis treatment is projected to expand considerably, potentially exceeding $1.1 billion by 2035. Electromed is positioning itself to capture a significant share of this expansion by focusing on patient access and physician education.

A critical strategic advantage is the company's success with insurance payers. Electromed reported that its therapies are now under contract for 86% of covered lives in the United States. This high level of reimbursement coverage is crucial, as it streamlines the prescription process for physicians and reduces out-of-pocket hurdles for patients, making the SmartVest system a more accessible option for chronic care management. By removing administrative and financial friction, the company can more effectively penetrate the large, untapped patient population.

The Engine Room: Operational and Sales Efficiency

Behind the headline numbers is a story of deliberate operational and sales force optimization. The 18.6% growth in the core homecare market was driven not just by market demand, but by a highly productive direct sales team. In the third quarter, the company's 57 sales representatives generated an annualized revenue of $1,168,000 per rep, handily exceeding the company's own target range of $1.0 million to $1.1 million.

Electromed continues to invest in this efficiency. The company is rolling out a new Salesforce-based CRM system and an E-Prescribe platform, both designed to automate administrative tasks and provide better analytics. These tools aim to free up sales representatives' time, allowing them to focus more on physician education and patient engagement.

On the manufacturing front, the company is reaping the benefits of an optimization plan completed at the beginning of the fiscal year. This initiative has helped sustain high gross margins—which stood at an impressive 78.8% in Q3—and provides enough production capacity to support growth for the next three years without major capital outlays. This "asset-light" approach allows the company to translate revenue growth directly into improved profitability. The powerful combination of rising sales, high gross margins, and controlled SG&A expenses is what fueled the 76% surge in operating income, demonstrating a business model that is scaling effectively.